SCM
VKTX icon

Steadfast Capital Management’s Viking Therapeutics VKTX Stock Holding History

Steadfast Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-52,000
Closed -$4.26M – 71
2024
Q1 		$4.26M Buy
+52,000
New +$2.31M 0.1% 52

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Steadfast Capital Management's VKTX Position: Q2 2024 in Review

Steadfast Capital Management sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 52,000 shares — an estimated $4.26M sold.

Steadfast Capital Management first reported a position in VKTX in Q1 2024 and held it in 1 quarter. The position peaked at $4.26M in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Steadfast Capital Management reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Steadfast Capital Management sold 52,000 Viking Therapeutics shares in Q2 2024, an estimated $4.26M.
  • Steadfast Capital Management first reported a position in Viking Therapeutics in Q1 2024 and held it in 1 quarter.
  • Steadfast Capital Management's Viking Therapeutics position peaked at $4.26M in Q1 2024.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Steadfast Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.